載入...
Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab
BACKGROUND: Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently s...
Na minha lista:
| 發表在: | Patient |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4383814/ https://ncbi.nlm.nih.gov/pubmed/25736164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40271-015-0120-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|